Veracyte, Inc. (VCYT) Stock Ticker
VCYT right now
Market factors today
Unlock the full VCYT picture
About Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
VCYT stock facts
| Ticker symbol | VCYT |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
| Market cap | $3.6B |
| CEO | Marc Stapley |
| Employees | 755 |
| Headquarters | South San Francisco, CA, US |
| IPO date | 2013-10-29 |
| Website | www.veracyte.com |
What you can see for VCYT on Tickr
Live VCYT price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the VCYT report.
Rankings
FAQ
What is the ticker symbol for Veracyte, Inc.?
The ticker symbol for Veracyte, Inc. is VCYT, listed on the NASDAQ.
What is VCYT?
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab…